Recent Updates
Recently added Catalysts

LY2409021 Reference Form

Phase 1

Healthy Volunteers | Small molecule | Other |Eli Lilly and Company|Last Updated: Mar 11, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment35
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01354496A Study of LY2409021 Formulations and the Effect of FoodPHASE1 COMPLETED 35Apr 1, 2011Oct 1, 2011Mar 11, 20191 Singapore
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Medium Test Form to Reference Form
Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose)

AUC from time 0 to infinity (AUC0-∞).

Pharmacokinetics, Maximum Concentration (Cmax): Medium Test Form to Reference Form
Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose)
Secondary Endpoints
Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Standardized High Fat Meal to Fasting
Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose)
Pharmacokinetics, Maximum Concentration (Cmax): Standardized High Fat Meal to Fasting
Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose)
Pharmacokinetics, Time to Maximum Concentration (Tmax)
Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Cohort 1 - LY2409021 reference formEXPERIMENTALA 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
Cohort 1 - LY2409021 medium test form fedEXPERIMENTALSingle 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
Cohort 1 - LY2409021 medium test form fastedEXPERIMENTALSingle 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
Cohort 2 - LY2409021 low test form fastedEXPERIMENTALSingle 20 mg LY2409021 test form with low particle size administered orally in the fasted state
Cohort 2 - LY2409021 medium test form fastedEXPERIMENTALSingle 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
Cohort 2 - LY2409021 high test form fastedEXPERIMENTALSingle 20 mg LY2409021 test form with high particle size administered orally in the fasted state
Interventions
NameTypeDescription
LY2409021 Reference FormDRUGAdministered orally
LY2409021 Test-Med Formulation (medium particle size)DRUGAdministered orally
LY2409021 Test-High Formulation (high particle size)DRUGAdministered orally
LY2409021 Test-Low Formulation (low particle size)DRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Must be healthy male or a healthy female who cannot become pregnant * Must have body mass index (BMI) of 18.5 to 32 kilograms per meter squared (kg/m²), inclusive * Blood pressure as well as blood and urine laboratory test results must be acceptable for the study * The veins m...

Countries:Singapore
Unlock Eligibility Criteria